Mdm2 inhibitors and combinations thereof
AssigneeNovartis AG
InventorsGiordano CAPONIGRO, Ensar HALILOVIC, Thomas HORN-SPIROHN, Joseph LEHAR
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a pharmaceutical combination comprising (a) an Mdm2 inhibitor and (b)(i) a MEK inhibitor and/or (b)(ii) Bcl2 inhibitor, particularly for use in the treatment of a cancer. This disclosure also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.
Claims27
A pharmaceutical combination comprising
- (a) (6S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-(4-chlorophenyl)-2-(2,4-dimethoxypyrimidin-5-yl)-1-(propan-2-yl)-5,6-dihydropyrrolo[3,4-d]imidazol-4(1H)-one, or a pharmaceutically acceptable salt thereof;
- and
- (b) ABT-199, or a pharmaceutically acceptable salt thereof.
2-6. (canceled)
(canceled)
(canceled)
(canceled)
22-27. (canceled)
(canceled)
(canceled)
36-41. (canceled)
Dependencies are inferred from the claim text.